289 related articles for article (PubMed ID: 12404155)
21. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.
Imamichi H; Crandall KA; Natarajan V; Jiang MK; Dewar RL; Berg S; Gaddam A; Bosche M; Metcalf JA; Davey RT; Lane HC
J Infect Dis; 2001 Jan; 183(1):36-50. PubMed ID: 11106537
[TBL] [Abstract][Full Text] [Related]
22. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
Resino S; M Bellón J; Gurbindo D; Tomás Ramos J; Antonio León J; Jose Mellado M; Angeles Muñoz-Fernández M
Clin Infect Dis; 2003 Nov; 37(9):1216-25. PubMed ID: 14557967
[TBL] [Abstract][Full Text] [Related]
23. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
24. Seminal reservoirs during an HIV type 1 eradication trial.
Nunnari G; Leto D; Sullivan J; Xu Y; Mehlman KE; Kulkosky J; Pomerantz RJ
AIDS Res Hum Retroviruses; 2005 Sep; 21(9):768-75. PubMed ID: 16218800
[TBL] [Abstract][Full Text] [Related]
25. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
Demonté D; Quivy V; Colette Y; Van Lint C
Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
[TBL] [Abstract][Full Text] [Related]
26. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
[TBL] [Abstract][Full Text] [Related]
27. Eradication of HIV in infected patients: some potential approaches.
Yang QE
Med Sci Monit; 2004 Jul; 10(7):RA155-65. PubMed ID: 15232518
[TBL] [Abstract][Full Text] [Related]
28. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
Hezareh M
Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
[TBL] [Abstract][Full Text] [Related]
29. Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradication.
Pomerantz RJ
Arch Immunol Ther Exp (Warsz); 2004; 52(5):297-306. PubMed ID: 15507870
[TBL] [Abstract][Full Text] [Related]
30. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
31. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
33. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
[TBL] [Abstract][Full Text] [Related]
34. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
35. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
36. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
[TBL] [Abstract][Full Text] [Related]
38. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert.
Kim HN; Tabet SR; Corey L; Celum CL
Vaccine; 2006 Jan; 24(4):532-9. PubMed ID: 16242816
[TBL] [Abstract][Full Text] [Related]
40. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
